ACADIA Pharmaceuticals develops and commercializes medicines for central nervous system disorders. Its best-known products include Nuplazid (pimavanserin) for hallucinations and delusions associated with Parkinson’s disease psychosis, and Daybue for Rett syndrome. The company focuses on underserved neurological and neuropsychiatric niches rather than broad primary-care markets, combining specialty sales with ongoing CNS research.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 244.3 | — | 19 | 15.2% |
| Q2 2025 | 264.6 | — | 26.7 | -19.3% |
| Q3 2025 | 278.6 | — | 71.8 | 116.4% |
| Q4 2025 | 284 | — | 273.6 | 91.2% |
| Q1 2026 | 268.1 | 9.7% | 3.6 | -80.8% |
| Q2 2026 | 308 | 16.4% | 31.5 | 18.1% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: National Beverage Corp. (FIZZ), Xenon Pharmaceuticals Inc. (XENE), TowneBank (TOWN), Star Bulk Carriers Corp. (SBLK), Freshpet, Inc. (FRPT), Viking Therapeutics, Inc. (VKTX)